CRISPR Technology Used to Target NRF2 Gene Linked to Chemotherapy Resistance in Lung Cancer

Researchers at ChristianaCare’s Gene Editing Institute have developed a new method using CRISPR gene-editing technology to address chemotherapy resistance in lung cancer. The study focuses on the NRF2 gene, which plays a key role in regulating cancer cells’ ability to resist treatment. This advancement introduces a precise approach to targeting genetic mechanisms that contribute to the failure of chemotherapy in certain cases of lung cancer.

The research highlights the NRF2 gene as a critical factor in enabling cancer cells to survive despite exposure to chemotherapy drugs. By utilizing CRISPR technology, scientists were able to modify this gene and disrupt its function, potentially reducing the resistance exhibited by these cells. The findings suggest that targeting NRF2 could pave the way for more effective treatments for patients with lung cancer who experience limited success with traditional chemotherapy approaches.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: November 17, 2025

Related posts:

AI and VR System Detects Autism in Kids with Over 85% Accuracy Patient-Centric Clinical Trial Software and Drug Pricing Models Discussed on June 24, 2025 Study Reveals Unique Structural Traits in Saururaceae Plastid Genomes and Their Evolutionary Implications Study Links Testosterone-to-DHT Ratio to Symptom Severity in Polycystic Ovary Syndrome

Author

GOAI